Giovanni Cappello

Dr. Giovanni Cappello

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Valentina GianniniValentina Giannini
Valentina Giannini
LPLaura Pusceddu
Laura Pusceddu
ADArianna Defeudis
Arianna Defeudis
GIULIA NICOLETTIGIULIA NICOLETTI
GIULIA NICOLETTI
GCGiovanni Cappello
Giovanni Cappello
DRDaniele Regge
Daniele Regge
The purpose of this paper is to develop and validate a delta-radiomics score to predict the response of individual colorectal cancer liver metastases (lmCRC) to first-line FOLFOX chemotherapy. Three hundred one lmCRC were manually segmented on both CT performed at baseline and after the first cycle of first-line FOLFOX, and 107 radiomics features were computed by subtracting textural features of CT at baseline from those at timepoint 1 (TP1). LmCRC were classified as nonresponders (R−) if they showed progression of disease (PD), according to RECIST1.1, before 8 months, and as responders (R+), otherwise. After feature selection, we developed a decision tree statistical model trained using all lmCRC coming from one hospital. The final output was a delta-radiomics signature subsequently validated on an external dataset. Sensitivity, specificity, positive (PPV), and negative (NPV) predictive values in correctly classifying individual lesions were assessed on both datasets. Per-lesion sensitivity, specificity, PPV, and NPV were 99%, 94%, 95%, 99%, 85%, 92%, 90%, and 87%, respectively, in the training and validation datasets. The delta-radiomics signature was able to reliably predict R− lmCRC, which were wrongly classified by lesion RECIST as R+ at TP1, (93%, averaging training and validation set, versus 67% of RECIST). The delta-radiomics signature developed in this study can reliably predict the response of individual lmCRC to oxaliplatin-based chemotherapy. Lesions forecasted as poor or nonresponders by the signature could be further investigated, potentially paving the way to lesion-specific therapies.

21 April 2021 in European Radiology
Verified
Journal Article
Closed access
PDF file
Roberto CannellaRoberto Cannella
Roberto Cannella
ETEmanuele Tabone
Emanuele Tabone
Giorgia PorrelloGiorgia Porrello
Giorgia Porrello
GCGiovanni Cappello
Giovanni Cappello
CGCecilia Gozzo
Cecilia Gozzo
TBTommaso Vincenzo Bartolotta
Tommaso Vincenzo Bartolotta

28 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Valentina GianniniValentina Giannini
Valentina Giannini
SMSimone Mazzetti
Simone Mazzetti
GCGiovanni Cappello
Giovanni Cappello
VDValeria Maria Doronzio
Valeria Maria Doronzio
LVLorenzo Vassallo
Lorenzo Vassallo
DRDaniele Regge
Daniele Regge
Recently, Computer Aided Diagnosis (CAD) systems have been proposed to help radiologists in detecting and characterizing Prostate Cancer (PCa). However, few studies evaluated the performances of these systems in a clinical setting, especially when used by non-experienced readers. The main aim of this study is to assess the diagnostic performance of non-experienced readers when reporting assisted by the likelihood map generated by a CAD system, and to compare the results with the unassisted interpretation. Three resident radiologists were asked to review multiparametric-MRI of patients with and without PCa, both unassisted and assisted by a CAD system. In both reading sessions, residents recorded all positive cases, and sensitivity, specificity, negative and positive predictive values were computed and compared. The dataset comprised 90 patients (45 with at least one clinically significant biopsy-confirmed PCa). Sensitivity significantly increased in the CAD assisted mode for patients with at least one clinically significant lesion (GS > 6) (68.7% vs. 78.1%, p = 0.018). Overall specificity was not statistically different between unassisted and assisted sessions (94.8% vs. 89.6, p = 0.072). The use of the CAD system significantly increases the per-patient sensitivity of inexperienced readers in the detection of clinically significant PCa, without negatively affecting specificity, while significantly reducing overall reporting time.

13 April 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
VVVanina Vani
Vanina Vani
DRDaniele Regge
Daniele Regge
GCGiovanni Cappello
Giovanni Cappello
MGMichela Gabelloni
Michela Gabelloni
ENEmanuele Neri
Emanuele Neri
Immunotherapy with checkpoint inhibitors (ICIs) is becoming standard of practice for an increasing number of cancer types. ICIs enhance T-cell action against the cancer cells. By unbalancing the immune system ICIs may cause dysimmune toxicities, a series of disorders broadly defined immune-related adverse events (irAEs). IrAEs may affect any organ or apparatus and most frequently involve skin, colon, endocrine organs, liver, and lungs. Early identification and appropriate treatment of irAEs can improve patient outcome. The paper aims at reviewing mechanisms of the occurrence of irAEs, the importance of a proper diagnosis and the main pillars of therapy. To provide effective guidance to the comprehension of major irAEs imaging findings will be reviewed.

1 January 2021 in BJR|Open
Verified
Journal Article
Open access
GCGiovanni Cappello
Giovanni Cappello
FMFrancesca Molea
Francesca Molea
Delia CampanellaDelia Campanella
Delia Campanella
FGFrancesca Galioto
Francesca Galioto
FRFilippo Russo
Filippo Russo
DRDaniele Regge
Daniele Regge
Cancer immunotherapy with immune-checkpoint inhibitors (ICIs) has emerged as an effective treatment for different types of cancer. ICIs are monoclonal antibodies that inhibit the signaling pathway that suppress antitumor T-cell activity. Patients benefit from increased overall and progression-free survival, but the enhancement of normal immunity can result in autoimmune manifestations, called immune-related adverse events (IRAEs), which may lead to a discontinuation of cancer therapy and to severe also life-threating events. IRAEs may affect any organs or system in the human body, being the gastrointestinal (GI) tract one of the most involved districts. Imaging plays an important role in recognizing GI IRAEs and radiologist should be familiar with the main spectrum of radiological appearance. Indeed, early detection of GI IRAEs is crucial for proper patient management and reduces morbidity and mortality. The purpose of this review is to present the most relevant imaging manifestation of GI IRAEs.

20 December 2023 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
GCGiovanni Cappello
Giovanni Cappello
VRVittorio Romano
Vittorio Romano
ENEmanuele Neri
Emanuele Neri
LFLaure Fournier
Laure Fournier
MDMelvin D’aNastasi
Melvin D’aNastasi
DRDaniele Regge
Daniele Regge
Objectives: To present the results of a survey on the assessment of treatment response with imaging in oncologic patient, in routine clinical practice. The survey was promoted by the European Society of Oncologic Imaging to gather information for the development of reporting models and recommendations. Methods: The survey was launched on the European Society of Oncologic Imaging website and was available for 3 weeks. It consisted of 5 sections, including 24 questions related to the following topics: demographic and professional information, methods for lesion measurement, how to deal with diminutive lesions, how to report baseline and follow-up examinations, which previous studies should be used for comparison, and role of RECIST 1.1 criteria in the daily clinical practice. Results: A total of 286 responses were received. Most responders followed the RECIST 1.1 recommendations for the measurement of target lesions and lymph nodes and for the assessment of tumor response. To assess response, 48.6% used previous and/or best response study in addition to baseline, 25.2% included the evaluation of all main time points, and 35% used as the reference only the previous study. A considerable number of responders used RECIST 1.1 criteria in daily clinical practice (41.6%) or thought that they should be always applied (60.8%). Conclusion: Since standardized criteria are mainly a prerogative of clinical trials, in daily routine, reporting strategies are left to radiologists and oncologists, which may issue local and diversified recommendations. The survey emphasizes the need for more generally applicable rules for response assessment in clinical practice. Critical relevance statement: Compared to clinical trials which use specific criteria to evaluate response to oncological treatments, the free narrative report usually adopted in daily clinical practice may lack clarity and useful information, and therefore, more structured approaches are needed. Key points: · Most radiologists consider standardized reporting strategies essential for an objective assessment of tumor response in clinical practice. · Radiologists increasingly rely on RECIST 1.1 in their daily clinical practice. · Treatment response evaluation should require a complete analysis of all imaging time points and not only of the last. Graphical